BioStock: Gabather’s lead candidate moves forward in the clinic

Swedish biotech Gabather has received the approval from the Portuguese authorities to go ahead with a target engagement study to complete the phase I evaluation of GT-002, the company’s candidate targeting mood disorders. As patient recruitment for the study proceeds, BioStock got in touch with CEO Michael-Robin Witt to learn more about the timeline for the study.

Read the interview with Michael-Robin Witt at biostock.se:

https://www.biostock.se/en/2022/06/gabathers-lead-candidate-moves-forward-in-the-clinic/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/